Analysis: NGL Fine-Chem Limited

NSE:NGLFINE Pharma - Animal Market cap: ₹1.8K cr

Growth thesis

NGL Fine Chem Ltd is an Indian API manufacturer specializing in veterinary pharmaceuticals for farm and companion animals, with 95% revenue from animal health APIs. Key segments include regulated (EU/US) and unregulated markets, driven by Phase II plant commissioning (H2 FY27) to add ₹350-400 crores turnover and six CEPs/nine DMS approvals by CY2026. Growth will accelerate from regulated market sales (Europe FY27, US FY28), a ₹150 crores quarterly revenue run rate by FY27, and EBITDA margin expansion to 15-18% via cost pass-through and capacity utilization. Over 2-3 years, the new plant’s 3-4 year ramp-up and Fluralaner’s post-patent launch (2027) will drive revenue scale, while margin stability depends on timely FDA/EMA approvals and avoiding Phase II delays from gas/labor constraints.

Why is NGL Fine-Chem Limited stock rising?

Phase II greenfield expansion commissioning delayed to early Q2 FY27, commercial production expected from H2 FY27
Partial price pass-through achieved with customers in Q1 FY27 to offset raw material and freight cost increases
Targeting EBITDA margin of 15% to 18%
Five VMS filed with US FDA; plan to file six more in the current year
Expecting three CEPs under review to be approved in H2 CY2026; two more CEPs to be submitted in the current quarter

Research report

companyname: NGL Fine-Chem Limited ticker: NGLFINE sector: Pharmaceuticals / Veterinary APIs NGL Fine-Chem Limited manufactures and exports Active Pharmaceutical Ingredients (APIs), advanced intermediates, and finished dosage forms for both animal and human health. Founded in 1981, the company has spent over four decades building deep expertise in veterinary APIs, where it holds a dominant position in key product categories. It operates three manufacturing units at Tarapur and Navi Mumbai, with...

Read the full report →

Catalysts

capex, margin expansion, regulatory approval, geographic expansion

Growth guidance

FY27 revenue growth guided at 150+ crores quarterly run rate driven by new capacity and volume expansion

Guidance upgraded

RS rating: 31 Stage: Stage 2

Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for NGL Fine-Chem Limited and 4,900+ companies.

5-day free pass. No card required.